IL1B and rheumatoid arthritis: In this study, the early treatment appeared to be beneficial as it resulted in a delayed onset of the disease (CIA onset on day 35) and alleviated the severity of the clinical symptoms, while it was also associated with a reduction in serum levels of the proinflammatory cytocides IL-17-, IL-1b-, and IL-17-triggering cytokines, which are particularly implicated in the pathogenesis of RA [83].